News

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense ...
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...
KPBS31m
Texas is relying on FEMA. State leaders said it should be cut
The governor and top emergency official in Texas are both members of a council advising the Trump administration on options ...